Protein tyrosine phosphatase 1B inhibition as a potential therapeutic target for chronic wounds in diabetes

Related Experiment Video

Updated: Dec 19, 2025

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

5.3K

Ana Figueiredo1, Ermelindo C Leal1, Eugénia Carvalho2

  • 1Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; Institute for Interdisciplinary Research, University of Coimbra, Portugal.

Pharmacological Research
|June 7, 2020
PubMed

Insights

Inhibiting protein tyrosine phosphatase 1B (PTP1B) shows promise for treating non-healing diabetic foot ulcers (DFUs). PTP1B inhibition aids wound healing by reducing inflammation and promoting tissue regeneration.

Area of Science:

  • Biochemistry
  • Diabetology
  • Wound Healing Research

Background:

  • Non-healing diabetic foot ulcers (DFUs) represent a growing clinical challenge with limited effective treatments, often leading to amputation.
  • Protein tyrosine phosphatase 1B (PTP1B), a key regulator of metabolic pathways, is overexpressed in diabetic conditions.
  • PTP1B plays a critical role in cellular processes relevant to tissue repair and inflammation.

Purpose of the Study:

  • To investigate the therapeutic potential of PTP1B inhibition in the context of diabetic wound healing.
  • To elucidate the mechanisms by which PTP1B modulation impacts DFU progression.
  • To identify PTP1B as a potential therapeutic target for improving DFU outcomes.

Main Methods:

  • Review of existing literature on PTP1B function in metabolic pathways and wound healing.
  • Analysis of PTP1B expression levels in diabetic tissues.
  • Exploration of the effects of PTP1B inhibition on key wound healing parameters in preclinical models (implied).

Main Results:

  • PTP1B inhibition has been demonstrated to enhance wound healing in diabetic models.
  • Reduced inflammation and bacterial infection at the wound site were observed with PTP1B inhibition.
  • Promotion of angiogenesis and tissue regeneration were key outcomes linked to PTP1B modulation.

Conclusions:

  • Pharmacological modulation of PTP1B activity presents a viable strategy for treating diabetic foot ulcers.
  • PTP1B inhibition emerges as a significant therapeutic target for improving diabetic wound healing and potentially preventing amputations.
Keywords:
Diabetic wound healingInflammationPTP1BTissue repair mechanismsTrodusquemine (PubChem CID: 9917968)

More Related Videos

Protocol to Create Chronic Wounds in Diabetic Mice06:55

Protocol to Create Chronic Wounds in Diabetic Mice

Published on: September 25, 2019

21.4K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.5K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.6K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
777
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
366